# Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

> **NCT04449861** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 166 (actual)

## Conditions studied

- Small Cell Lung Carcinoma Extensive Disease

## Interventions

- **DRUG:** Durvalumab plus chemotherapy

## Key facts

- **NCT ID:** NCT04449861
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04449861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04449861, "Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04449861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*